Parse Biosciences secured a court ruling that invalidated a Scale Biosciences patent now owned by 10x Genomics, removing one asserted claim in ongoing patent litigation. A U.S. District Court found the challenged claims lacked sufficient written description and enablement, weakening the intellectual property case against Parse. The decision represents a notable development in the high‑stakes legal battles among single‑cell sequencing companies, with implications for market competition in instrument‑free single‑cell library preparation approaches.